A cheaper version of the new drug anti-blood clotting drug prasugrel has been launched in India.
The generic prasugrel under the brand name Prasita is being marketed in India by Daiichi-Ranbaxy.
Prasita is is an antiplatelet drug for the prevention of blood clots in blood vessels in patients. It is used to remove blood clots while putting stents (angioplasty) to open up blood vessels blocked by clots.
Prasita (prasugrel) can help reduce the risk of a future heart-related event, such as a heart attack or stent clot, in patients who had an acute coronary syndrome (ACS) event that was treated with angioplasty.
Prasita (prasugrel) keeps platelets from sticking together and causing a blockage in an artery. Blood clots are a major cause of heart attacks.
Aspirin is a type of antiplatelet medicine that helps protect you in a different way than your prescription antiplatelet medication. Prasita (prasugrel) and aspirin work together to help keep platelets from sticking together and causing blockages (clots) in the arteries of your heart, thereby helping to reduce the risk of a future heart attack.
Antiplatelet medicines like Prasita (prasugrel) reduce the ability of blood to clot, which is a good thing when it comes to your stent and the arteries of your heart.
On the other hand, because your blood doesn’t clot as well, antiplatelet medicines can also increase the risk of bleeding.
Bleeding is the most common side effect of anti-platelets drugs such as Prasita (prasugrel). Some bleeding can be life threatening and even fatal.
Prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding in patients with acute coronary syndromes with scheduled percutaneous coronary intervention.
Prasugrel, which is sold elsewhere in the brand name Effient was compared to the other leading anti-platelet drug clopidogrel (Plavix) in a clinical study that involved 13,608 patients with acute coronary syndrome who underwent angioplasty.
In this study, about half of the patients received Effient and aspirin, and the other half received Plavix and aspirin. On average, patients in the study were treated for about 15 months.
Another recent study found that prasugrel (Effient) has been cost-effective for patients with heart disease compared to the leading clot-buster clopidogrel (Plavix).
Ranbaxy Laboratories, a subsidiary of Daiichi Sankyo Co of Japan, has launched a generic version of Prasugrel in India.
Following the April 2009 launch of Olvance (olmesartan medoxomil), an antihypertensive originally discovered by Daiichi Sankyo, Prasita is the second product from the Daiichi Sankyo portfolio to be introduced in India.
Ranbaxy will create awareness, understanding and acceptance of the new antiplatelet therapy among the target audiences in the country.